University of Iowa, 200 Hawkins Drive
Welcome,         Profile    Billing    Logout  
 15 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mathews, Katherine
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
ENVISION, NCT05881408 / 2020-002372-13: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
3
148
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
05/27
06/28
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Completed
2/3
56
Europe, Canada, US, RoW
Tideglusib, Placebo
AMO Pharma Limited
Congenital Myotonic Dystrophy
04/23
04/23
REACH CDM X, NCT05004129: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Recruiting
2/3
76
Canada, US, RoW
Tideglusib
AMO Pharma Limited
Congenital Myotonic Dystrophy
03/25
03/25
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Active, not recruiting
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
01/29
LION-CS101, NCT05230459: A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Recruiting
1/2
10
US
AB-1003 dose level 1, AB-1003 dose level 2, Placebo
Asklepios Biopharmaceutical, Inc.
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
12/28
12/28
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27
GRASP-01-002, NCT05257473: Defining Endpoints in Becker Muscular Dystrophy

Recruiting
N/A
80
Europe, US, RoW
Virginia Commonwealth University, Edgewise Therapeutics, Inc.
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
05/25
05/26
NCT00313677: Clinical Trial Readiness for the Dystroglycanopathies

Recruiting
N/A
190
US
Katherine Mathews, National Institute of Neurological Disorders and Stroke (NINDS)
Muscular Dystrophy
07/25
07/26
GRASP-01-003, NCT05618080: LGMD R1 Natural History Study

Recruiting
N/A
100
Europe, US
Virginia Commonwealth University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Florida, University of Minnesota, Newcastle University, University of Kansas Medical Center, University of Colorado, Denver, Indiana CHC (Community Health Clinic), University of California, Irvine
Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
05/28
08/28
FA-COMS, NCT03090789: FA Clinical Outcome Measures

Active, not recruiting
N/A
2000
Canada, US, RoW
Friedreich's Ataxia Research Alliance, University of Rochester, Children's Hospital of Philadelphia
Friedreich Ataxia, Neuro-Degenerative Disease
01/30
01/30
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38
UNIFAI, NCT06016946: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Recruiting
N/A
3000
Europe, Canada, US, RoW
Friedreich's Ataxia Research Alliance
Friedreich Ataxia
01/48
01/48
Campbell, Kevin
NCT05381831: Natesto Spermatogenesis Reboot

Recruiting
4
30
US
NatestoTM
University of Florida, Acerus Pharmaceutical
Hypogonadism, Male
12/24
12/24
NCT00313677: Clinical Trial Readiness for the Dystroglycanopathies

Recruiting
N/A
190
US
Katherine Mathews, National Institute of Neurological Disorders and Stroke (NINDS)
Muscular Dystrophy
07/25
07/26
Moore, Steven A
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed
4
3591
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
01/24
NCT05907850: Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

Recruiting
1
400
US
Riboflavin, Riboflavin 100mg capsules, Placebo, Placebo capsule
Steven Moore, Racing the Planet
Muscle Soreness
12/24
12/24
NCT00313677: Clinical Trial Readiness for the Dystroglycanopathies

Recruiting
N/A
190
US
Katherine Mathews, National Institute of Neurological Disorders and Stroke (NINDS)
Muscular Dystrophy
07/25
07/26
NCT00339495: Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

Active, not recruiting
N/A
154900
US
National Cancer Institute (NCI)
Cancer, Death
12/25
12/25
Stephan, Carrie
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27
GRASP-01-002, NCT05257473: Defining Endpoints in Becker Muscular Dystrophy

Recruiting
N/A
80
Europe, US, RoW
Virginia Commonwealth University, Edgewise Therapeutics, Inc.
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
05/25
05/26
GRASP, NCT03981289: Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Active, not recruiting
N/A
80
Europe, US
Virginia Commonwealth University, Newcastle University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Minnesota, University of California, Irvine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Colorado, Denver, University of Kansas Medical Center
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
06/25
06/25
NCT00313677: Clinical Trial Readiness for the Dystroglycanopathies

Recruiting
N/A
190
US
Katherine Mathews, National Institute of Neurological Disorders and Stroke (NINDS)
Muscular Dystrophy
07/25
07/26
GRASP-01-003, NCT05618080: LGMD R1 Natural History Study

Recruiting
N/A
100
Europe, US
Virginia Commonwealth University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Florida, University of Minnesota, Newcastle University, University of Kansas Medical Center, University of Colorado, Denver, Indiana CHC (Community Health Clinic), University of California, Irvine
Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
05/28
08/28
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38

Download Options